Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus by Dzyurkevich M. et al.
Scientific Reports, 2017, vol.7, N1
Pyridoxine dipharmacophore derivatives as potent
glucokinase activators for the treatment of type 2
diabetes mellitus
Dzyurkevich M., Babkov D., Shtyrlin N., Mayka O., Iksanova A., Vassiliev P., Balakin K., Spasov
A., Tarasov V., Barreto G., Shtyrlin Y., Aliev G.
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
© 2017 The Author(s). Glucokinase is one of the promising targets for glucose-lowering agents,
and the development  of  GK activators  are now considered as  one of  the most  promising
strategies for the treatment of type 2 diabetes mellitus. In this work, a series of novel symmetric
molecular  constructs,  in  which two pyridoxine moieties are connected via sulfur-containing
linkers, have been synthesized and tested in vitro for glucokinase activation potential.  The
enzyme activation rates by two most active compounds at 100 μM (~150% and 130%) were
comparable to that of the reference agent PF-04937319 (~154%). Both leading compounds
demonstrated low cytotoxicity and excellent safety profile in acute toxicity experiment in rats
after oral administration with LD 50 exceeding 2000 mg/kg of body weight. Binding mode of the
active compounds in comparison with the reference agent was studied using molecular docking.
The leading compounds represent viable preclinical candidates for the treatment of type 2
diabetes mellitus, as well as a promising starting point for the design of structural analogs with
improved activity.
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